Lupin’s Visionary Win: CHMP Backs Biosimilar Ranibizumab

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Lupin has received a positive CHMP opinion for its biosimilar ranibizumab (Ranluspec™), covering vial and syringe formats. The drug treats retinal conditions like AMD, DME, and RVO. This regulatory milestone positions Lupin to expand in Europe’s ophthalmology market, offering affordable biologics and strengthening its biosimilars portfolio.